Nevertheless, the lack of targeted therapy in non-BRAF mutant melanomas, the eventual progression during treatment with BRAF/MEK inhibitors, and the high rate of somatic mutations in melanomas relative to other malignancies advocates for further research into their biological effects on tumor progression [33,36]. This evidence concerns the gene MAP2K7 and neoplasm.